Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...